>>3 Dividend Stocks for a Richer Retirement<< (sponsored)
ETF Channel ETF Channel ETF holdings and exposure research

Sum Up The Parts: ESML Could Be Worth $50


Joel Kornblau, Editor, ETF Channel - Tuesday, August 12, 2025, 7:43 AM

At an office desk, the monitor is open to an ETF Market Overview heatmap, and there is a notepad on the desk with investment allocation notes; on the wall, a sign says Discipline, Diversification, Discovery.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $49.84 per unit.

With ESML trading at a recent price near $41.83 per unit, that means that analysts see 19.16% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of ESML's underlying holdings with notable upside to their analyst target prices are IDEAYA Biosciences Inc (IDYA), Klaviyo Inc (KVYO), and CRISPR Therapeutics AG (CRSP). Although IDYA has traded at a recent price of $22.84/share, the average analyst target is 102.34% higher at $46.21/share. Similarly, KVYO has 48.99% upside from the recent share price of $30.07 if the average analyst target price of $44.80/share is reached, and analysts on average are expecting CRSP to reach a target price of $80.74/share, which is 45.71% above the recent price of $55.41. Below is a twelve month price history chart comparing the stock performance of IDYA, KVYO, and CRSP:

IDYA, KVYO, and CRSP Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
iShares ESG Aware MSCI USA Small-Cap ETF ESML $41.83 $49.84 19.16%
IDEAYA Biosciences Inc IDYA $22.84 $46.21 102.34%
Klaviyo Inc KVYO $30.07 $44.80 48.99%
CRISPR Therapeutics AG CRSP $55.41 $80.74 45.71%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on IDYA — FREE
Get the latest Zacks research report on KVYO — FREE
Get the latest Zacks research report on CRSP — FREE



« Back

Featured ETF Research

Browse ETF screens, holdings-related research, dividend and yield pages, analyst screens, and related market idea pages from across the channel network. These links are grouped by topic to make the list easier to scan.

Dividend, Yield, and Income Research

Dividend and income-oriented screens that are relevant to ETF investors comparing holdings, yield exposure, and stock selection ideas.

Energy, Metals, and Canada Research

Cross-network sector research pages that may be useful for investors following ETF exposure to energy, metals, and Canadian markets.

Featured News Links

Sum Up The Parts: ESML Could Be Worth $50 | www.ETFChannel.com | Copyright © 2009 - 2026, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.